Synthetic polypeptide epitope based vaccine composition
AssigneeBharat Biotech International Limited
InventorAmit Raychoudhuri
Life of this patent
Estimating the term…
Abstract
Conserved epitopes selected from EV71 and CVA16, the two major causative agents of Hand Foot and Mouth Disease has been used to develop sub-unit bivalent vaccine antigen construct. The said vaccine described in this invention is capable to provide cross-protection to diverse EV71 and CVA16 infection causing strains. Further disclosed are the expression of the multi-epitope vaccine antigen coding gene and the purification process involved thereof. This present invention also discloses vaccine formulations against Hand Foot and Mouth Disease and other enterovirus infections comprising the recombinant vaccine antigen construct of the present invention.
Claims17
An immunogenic composition for inducing an immune response against Hand Foot and Mouth Disease caused by EV71 and CA16 comprising:
- a. an antigen that is a synthetic construct selected from the recombinant protein sequences as represented by SEQ ID No. 2 (named as MEV1) and SEQ ID No. 4 (named as MEV2);
- b. one or more adjuvants;
- c. one or more stabilizers;
- and
- d. a physiologically acceptable buffer selected from phosphate or citrate buffer;
- wherein the immunogenic composition is stable for at least 2 years at 5±3° C. and up to 2 weeks at 37° C.
A composition comprising a multi-epitope synthetic protein sequence as disclosed in SEQ ID No. 2, the composition having at least 92%-96% purity.
A composition comprising a multi-epitope synthetic protein sequence as disclosed in SEQ ID No. 4, the composition having with at least 96% purity.
Dependencies are inferred from the claim text.